在精准医学领域中，靶向肿瘤和血液疗法的临床试验已经变得异常复杂。 Whether you need support with early phase adaptive trial design, site selection, patient identification or targeted services for late-phase oncology trials, partner with a CRO, focused on oncology, who can enable you to improve the health and lives of those who desperately need it.
Working with gene and cell therapies, such as cell-based immunotherapies and CAR T-cell requires a multi-pronged approach that goes beyond traditional clinical trials. From discovery to market, you can apply biomarker identification strategies, companion diagnostics, multi-level stratification designs and composite endpoints.
Leverage our experience with more than 140 immuno-oncology studies, including innovative CAR T studies. 然后，使用我们专有的数据工具选择高性能肿瘤学研究中心、吸引投资者、评估方案设计并确定潜在肿瘤学和免疫肿瘤学参与者的地理分布。
More than 90% of our Phase II & III oncology trials are delivered on-time in study startup. You’ll get access to novel technologies like Xcellerate Monitoring that helps proactively safeguard patient safety and improve data quality as well as Xcellerate Insights that gives you a secure, shared view of your oncology trial’s latest operational metrics. 项目经理和法规负责人团队可帮助您实现里程碑。 Finally, leverage our established relationships with oncology investigators, local and international key opinion leaders (KOLs), global collaborative groups and patient networks to help your cancer trial run efficiently.